Reported Earnings • May 31
First quarter 2026 earnings released: CA$0.002 loss per share (vs CA$0.005 loss in 1Q 2025) First quarter 2026 results: CA$0.002 loss per share (improved from CA$0.005 loss in 1Q 2025). Revenue: CA$160.7k (down 38% from 1Q 2025). Net loss: CA$409.4k (loss narrowed 24% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings. Tillkännagivande • May 22
Promino Nutritional Sciences Inc. announced that it has received CAD 0.95931 million in funding On May 21, 2026, Promino Nutritional Sciences Inc. closed the transaction. The company issued 3,000,000 units at a price of CAD 0.03 per Unit for gross proceeds of CAD 90,000 in its final tranche. In aggregate, the Company issued 31,976,999 Units for gross proceeds of CAD 959,309.97 in its private placement. The Units are composed of one Share and one half of one Share purchase warrant, each whole warrant exercisable into one additional Share at a price of CAD 0.06 for one year from the date of issuance. All securities issued upon closing of the Final Tranche are subject to a four-month hold period in accordance with applicable securities laws. Tillkännagivande • Apr 10
Promino Nutritional Sciences Inc. Launches NCAA Division I Athlete Platform Through Multi-Sport Nil Partnership with Virginia Military Institute Promino Nutritional Sciences Inc. announced a multi-sport Name, Image and Likeness ("NIL") partnership with eight NCAA Division I student-athletes at the Virginia Military Institute ("VMI"). This agreement marks the formal launch of the Promino NCAA Athlete Platform, a strategic initiative designed to provide collegiate athletes with the Company's NSF Certified for Sport® proprietary amino acid formulations. The partnership includes eight cadet-athletes across VMI's Division I programs, who will integrate the formulation into their training and recovery protocols. The Company intends to utilize this multi-sport program as a model for potential expansion into additional NCAA athletic programs, subject to future agreements. Promino's performance platform is engineered to support muscle protein synthesis and recovery through precise, low-calorie formulations. Unlike traditional protein formats that require lengthy digestion, Promino's proprietary ratio is designed for rapid absorption, delivering muscle-building support without "digestive drag" or excess calories. Its core product, Rejuvenate Muscle Health™, is a clinically researched proprietary amino acid formula designed to rebuild, restore, and rejuvenate muscle tissue. The Company also produces Promino™ - NSF Certified for Sport®. Tillkännagivande • Mar 14
Promino Nutritional Sciences Inc. announced that it expects to receive CAD 1.2 million in funding Promino Nutritional Sciences Inc announced a non brokered private placement to issue 40,000,000 units of the Company ("Units") at a price of CAD 0.03 per Unit for gross proceeds of CAD 1,200,000 on March 13, 2026. Each Unit will consist of one common share and one half of one common share purchase warrant with each Warrant being exercisable to purchase one additional Share at a price of CAD 0.06 for twelve months from the date of issuance. The Company may pay finders' fees in connection with the Offering, as permitted by applicable securities laws and the rules of the Canadian Securities Exchange. The Offering is expected to close on or about April 15, 2026 and is subject to execution of subscription agreements by the placees and to certain conditions including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the Canadian Securities Exchange. All securities issued in connection with the Offering will be subject to a four month and one day statutory resale restriction pursuant to applicable Canadian securities laws. Tillkännagivande • Dec 19
Promino Nutritional Sciences Inc. announced that it expects to receive CAD 1.5 million in funding Promino Nutritional Sciences Inc announced a non-brokered private placement to issue 50,000,000 units at an issue price of CAD 0.02 for the proceeds of CAD 1,000,000 on December 18, 2025. The company may increase the size of the new offering by up to 25,000,000 additional units. Each unit will consist of one common share and one common share purchase warrant, with each warrant being exercisable to purchase one additional share at a price of CAD 0.06 for 12 months from the date of issuance. The new offering is expected to close on or about January 30, 2026, and is subject to conditions including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the Canadian Securities Exchange. All securities issued in connection with the new offering will be subject to a four-month-and-one-day statutory resale restriction pursuant to applicable Canadian securities laws.
On the same day the company amended the terms of the transaction. The company will now issue 50,000,000 units at an issue price of CAD 0.03 for gross proceeds of CAD 1,500,000. All other offering terms remain unchanged. Tillkännagivande • Dec 10
Promino Nutritional Sciences Inc., Annual General Meeting, Feb 12, 2026 Promino Nutritional Sciences Inc., Annual General Meeting, Feb 12, 2026. Tillkännagivande • Dec 09
Promino Nutritional Sciences Inc. announced that it expects to receive CAD 1 million in funding Promino Nutritional Sciences Inc. announced non-brokered private placement of 15% secured convertible debentures due December 3, 2028 for an aggregate principal amount of up to CAD 1,000,000 on December 9, 2025. The Company may increase the size of the Offering by up to an additional CAD 500,000 of Convertible Debentures for aggregate gross proceeds of up to CAD 1,500,000. Each Convertible Debenture will consist of a CAD 1,000 principal amount and be secured against company's present and after-acquired inventory. The Convertible Debentures will bear interest at a rate of 15% per annum, payable quarterly in, at the election of the company, cash or common shares of the Company at a conversion price of the greater of (i) CAD 0.05 and (ii) the five-day VWAP of the Shares prior to the interest payment date. The principal amount outstanding under the Convertible Debentures will be, at the election of the company, payable in cash or convertible into Shares at a conversion price of CAD 0.05 per Share on maturity three (3) years from the date of issuance (the "Maturity Date"). The company may also elect to repay the principal amount of the Convertible Debentures in cash, in whole or in part, at any time prior to the Maturity Date. The Convertible Debentures shall be convertible at the option of the holder, in whole or in part, and at any time prior to the Maturity Date, into Shares at a conversion price of CAD 0.05 per Share. The Offering is subject to the approval of the Canadian Securities Exchange ("CSE"). The Convertible Debentures and the Shares issuable upon conversion of the Convertible Debentures or any interest thereon will be subject to a four month and one day statutory resale restriction pursuant to applicable Canadian securities laws. The Offering is expected to close on or about January 30, 2026 and is subject to execution of subscription agreements by the placees and to certain conditions including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the CSE. The company also announces that it has granted 500,000 options to purchase Shares, with an exercise price of CAD 0.05 and maturity date of December 3, 2028, to a consultant of the Company. The securities issued under this grant are subject to a four month and one day statutory resale restriction pursuant to applicable Canadian securities laws. Tillkännagivande • Apr 04
Promino Nutritional Sciences Inc. announced that it has received CAD 0.86405 million in funding On April 3, 2025, Promino Nutritional Sciences Inc closed the transaction. The company issued 10,881,000 Units at a price of CAD 0.05 per Unit for gross proceeds of CAD 544,050. The company paid cash finder's fees in the aggregate amount of CAD 35,073.50 and issued an aggregate of 701,470 non-transferable finder's unit warrants. Tillkännagivande • Sep 18
Promino Nutritional Sciences Inc. Begins Preclinical Trial to Demonstrate Effectiveness of Promino™ Patented IP for Retention of Muscle Mass in Cancer Patients Undergoing Aggressive Chemotherapy Treatment Promino Nutritional Sciences Inc. has announced the commencement of the preclinical trial to demonstrate the effectiveness of the Promino™ patented IP for the retention of muscle mass in cancer patients undergoing aggressive chemotherapy treatment. The preclinical trial will be led by Dr. Patrick Gunning, who was appointed as special advisor to the Company on May 8, 2024 to conduct these trials. Results of the preclinical trials are expected in 10 weeks. If testing affirms the effectiveness of the patented IP in retaining muscle mass in chemotherapy patients, the Company will likely develop a specialized formulation specifically for marketing to the practitioner channel in North America. Tillkännagivande • Sep 09
Promino Nutritional Sciences Inc. Announces the Release of Results of A New Human Clinical Trial Promino Nutritional Sciences Inc. announced the release of results of a new human clinical trial led by Dr. Robert R. Wolfe, Phd. The trial found that a 3.6 gram serving of Rejuvenate Muscle ActivatorTM has the same effect on muscle protein synthesis as 40 grams of whey protein. The clinical trial measured protein equivalency between the patented essential amino acid blend underlying Rejuvenate Muscle ActivatorTM and ProminoTM versus traditional whey protein, long considered the leader in muscle health. The patented amino acid blend was found to be 11x more effective than whey protein isolate gram-for-gram. Research from Dr. Wolfe and his team at the University of Arkansas can be found here. Promino is the exclusive licensor of the patent for the global mass consumer and sports nutrition markets. The patent is the result of over 20 years of research, over 25 clinical trials and funding of over USD 20 million. The Company recently re-launched Rejuvenate Muscle ActivatorTM (3.6 gram serving), marketed to the mass active nutrition and wellness category, and ProminoTM- NSF Certified for Sport® (11 gram serving), designed for professional and collegiate athletes and sports nutrition channels. The results of the clinical trial demonstrate the commercial value of the patented blend by supporting its efficiency, cost effectiveness and clean formula. Reported Earnings • Sep 05
Second quarter 2024 earnings released: CA$0.042 loss per share (vs CA$0.028 loss in 2Q 2023) Second quarter 2024 results: CA$0.042 loss per share (further deteriorated from CA$0.028 loss in 2Q 2023). Revenue: CA$11.6k (down 90% from 2Q 2023). Net loss: CA$2.72m (loss widened 161% from 2Q 2023). Tillkännagivande • Jul 10
Promino Nutritional Sciences Inc. announced that it has received CAD 1.749001 million in funding On July 9, 2024, Promino Nutritional Sciences Inc. closed the transaction. The company issued 166,666 Units at a price of CAD 0.18 per Unit for gross proceeds of CAD 29,999.88 in second and final tranche. Each Unit comprised of one common share and one common share purchase warrant. Each warrant is exercisable to acquire one common share of the Company at a price of CAD 0.30 per share for a period of 24 months from the date of issuance. Together with the first tranche, the Company has issued an aggregate of 9,716,671 Units for gross proceeds of CAD 1,749,000.78. All securities issued in connection with the second tranche are subject to a hold period of four months and one day pursuant to applicable securities laws. The Company did not pay any finder’s fees, in cash nor securities, in connection with the second tranche. Tillkännagivande • May 15
Promino Nutritional Sciences Inc., Annual General Meeting, Jul 09, 2024 Promino Nutritional Sciences Inc., Annual General Meeting, Jul 09, 2024. Location: british columbia, vancouver Canada Reported Earnings • May 09
Full year 2023 earnings released: CA$0.15 loss per share (vs CA$0.29 loss in FY 2022) Full year 2023 results: CA$0.15 loss per share (improved from CA$0.29 loss in FY 2022). Revenue: CA$478.2k (down 88% from FY 2022). Net loss: CA$5.81m (loss narrowed 44% from FY 2022). Tillkännagivande • Apr 30
Promino Nutritional Sciences Inc. (CNSX:MUSL) entered into a binding letter of intent to acquire Helios Helium Corp. for CAD 5.84 million. Promino Nutritional Sciences Inc. (CNSX:MUSL) entered into a binding letter of intent to acquire Helios Helium Corp. for CAD 5.84 million on April 29, 2024. Total share consideration is expected to be approximately 36.5 million Promino common shares. Pursuant to the LOI, Helios will spin out its helium property and sundry assets into a new entity, such that Helios’ assets will only be comprised of cash and certain marketable securities. Thereafter, each shareholder of Helios will receive one common share of the Company in exchange for each common share of Helios held. Completion of the Transaction will be subject to the satisfaction or waiver of customary conditions, including the satisfactory completion of due diligence, the entering into of a definitive agreement for the proposed Transaction and the receipt of all necessary approvals and consents, including regulatory, corporate, court and shareholder approval, if applicable. New Risk • Feb 13
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 52% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (37% average weekly change). Negative equity (-CA$7.7m). Earnings have declined by 18% per year over the past 5 years. Shareholders have been substantially diluted in the past year (52% increase in shares outstanding). Revenue is less than US$1m (CA$265k revenue, or US$197k). Minor Risk Market cap is less than US$100m (€10.1m market cap, or US$10.8m). Tillkännagivande • Feb 07
Promino Nutritional Sciences Inc. announced that it has received CAD 2.208075 million in funding On February 6, 2024, Promino Nutritional Sciences Inc. closed the transaction. The company issued 44,161,500 units at an issue price of CAD 0.05 for the gross proceeds of up to CAD 2,208,075. Each unit will be comprised of one common share of the company and one-half of one common share purchase warrant, with each whole warrant exercisable to acquire one common share of the company at a price of CAD 0.10 per share for a period of 24 months from the date of issuance. All securities issued in connection with the offering will be subject to a statutory hold period of four months and one day. The company paid cash finder's fees in the aggregate amount of CAD 113,570 and issued2,271,400 finder's warrants to certain finders who introduced purchasers to the Company. Each finder's warrant is exercisable to acquire one common share of the Company at a price of CAD 0.10 per share for a period of 24 months from the date of issuance. The transaction included participation from an insider of the Company for 1,000,000 Units. New Risk • Nov 30
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$2.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.1m free cash flow). Share price has been highly volatile over the past 3 months (28% average weekly change). Negative equity (-CA$7.7m). Earnings have declined by 18% per year over the past 5 years. Revenue is less than US$1m (CA$265k revenue, or US$195k). Market cap is less than US$10m (€3.22m market cap, or US$3.51m). Minor Risk Shareholders have been diluted in the past year (6.4% increase in shares outstanding). Tillkännagivande • Oct 12
Element Nutritional Sciences Inc. Appoints Adam Berk as Advisor Element Nutritional Sciences Inc. announced the appointment of Adam Berk as an independent Advisor to aid the Company to accelerate commercialization of its RejuvenateTM and PROMINO TM brands. Most recently, Mr. Berk was President of a renowned nutraceutical and vitamin company where he aided in acquisitions and helped grow the brand. Mr. Berk's most notable experience also includes over five years as Chairman and CEO of Stem Holdings Inc., three years as CEO of HYD for Men, and Co-CEO of Osmio, LLC. New Risk • Aug 27
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Negative equity (-CA$5.6m). Earnings have declined by 24% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (2.8% increase in shares outstanding). Revenue is less than US$5m (CA$1.8m revenue, or US$1.3m). Market cap is less than US$100m (€10.1m market cap, or US$11.0m). Tillkännagivande • Aug 04
Element Nutritional Sciences Inc. Rethinks Protein with Launch of Exclusive Patented PROMINO™ Brand Drink Mix and Ready-to-Drink Beverages Element Nutritional Sciences Inc. is preparing the professional sports world for the launch of its PROMINO™ drink mix and ready-to-drink beverage by working closely with pro athletes in their "offices" – elite training facilities and locker rooms across the multiple pro sports leagues in North America. PROMINO™ is NSF Certified for sport, which means it is free of banned substances and approved by all major sports leagues. Additionally, Element invested in a rigorous flavoring process with a top tier U.S. flavor house responsible for creating the taste of several of North America's best-selling sports nutrition beverages. Followed by extensive in-market consumer testing, the Company will launch two refreshing fruit flavors in fourth quarter of 2023. In addition to great taste, PROMINO™ delivers: Less than 15 calories per serving; No fat, no sugar, no dairy; 100% plant-based formula and Increases muscle protein synthesis by 76%, more than two times the 35% delivered by whey protein. PROMINO's patented amino acid formula contains the essential building blocks of protein and are shown to be the higher quality protein source in the world based on the rising gold standard of protein quality – DIAAS – which measures the uptake of these key amino acids in the gut. With a 321 DIAAS (Digestible Indispensable Amino Acid Score), PROMINO™ is superior to whey protein at 133. PROMINO™ is more effective than whey protein at producing the desired results – with none of the fat, sugar, carbs and bloat. It is a significant step forward for pro and collegiate athletes. Tillkännagivande • Jul 15
Element Nutritional Sciences Inc. announced that it has received CAD 1.9065 million in funding On July 14, 2023, Element Nutritional Sciences Inc. closed the transaction. The company has amended the terms of the transaction. The company received CAD 780,000 in its second and final tranche. The company has received CAD 1,906,500 in the transaction. The Company paid finder’s fees in the aggregate amount of CAD 17,000 to certain arm’s-length parties who introduced purchasers to the Company. New Risk • Jun 18
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$3.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$3.7m free cash flow). Share price has been highly volatile over the past 3 months (27% average weekly change). Negative equity (-CA$5.6m). Earnings have declined by 24% per year over the past 5 years. Minor Risks Revenue is less than US$5m (CA$1.8m revenue, or US$1.4m). Market cap is less than US$100m (€14.1m market cap, or US$15.5m). Reported Earnings • Jun 17
Full year 2022 earnings released: CA$0.097 loss per share (vs CA$0.10 loss in FY 2021) Full year 2022 results: CA$0.097 loss per share. Revenue: CA$4.00m (up 70% from FY 2021). Net loss: CA$10.3m (loss widened 18% from FY 2021). Tillkännagivande • Jun 08
Element Nutritional Sciences' Rejuvenate™ Muscle Activator Scores Ahead of Popular Protein Sources in Protein Quality Measurement Element Nutritional Sciences Inc. announced that its patented Rejuvenate™ Muscle Activator has recorded a score of 321 on the digestible indispensable amino acid score ("DIAAS"), a new and innovative protein quality measurement score recommended by the Food and Agriculture Organization. Rejuvenate™ Muscle Activator's score of 321 compares to a score of 1332 for whey protein (141% higher), 912 for soy protein (252% higher) and 822 for pea protein (291% higher). The market for protein-based beverages is large, with the whey protein market alone currently estimated to be $5.3 billion and expected to increase to over $11.2 billion by 20303. The DIAAS score accounts for the digestibility of amino acids absorbed by the body and the protein's contribution to human amino acid requirements. Rejuvenate™ Muscle Activator is composed of plant-based materials that are considered to be more digestible as it relates to calculating the DIAAS score. Tillkännagivande • Jan 17
Element Nutritional Sciences' RejuvenateTM Muscle Activator Now on Shelves at Shoppers Drug Mart and Loblaws Element Nutritional Sciences Inc. announced that the company's RejuvenateTM Muscle Activator stick packs are now on shelves at 700 Shoppers Drug Mart and Loblaws locations in Canada, adding 1,269 points of distribution for the company and bringing total points of distribution in North America to 33,000. Tillkännagivande • Dec 26
Element Nutritional Sciences Inc., Annual General Meeting, Feb 21, 2023 Element Nutritional Sciences Inc., Annual General Meeting, Feb 21, 2023. Reported Earnings • Dec 01
Third quarter 2022 earnings released: CA$0.023 loss per share (vs CA$0.031 loss in 3Q 2021) Third quarter 2022 results: CA$0.023 loss per share (improved from CA$0.031 loss in 3Q 2021). Revenue: CA$569.5k (down 11% from 3Q 2021). Net loss: CA$2.59m (loss narrowed 14% from 3Q 2021). Board Change • Nov 16
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 2 experienced directors. No highly experienced directors. CFO, Corporate Secretary & Director Shaun Power is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Sep 01
Second quarter 2022 earnings released: CA$0.016 loss per share (vs CA$0.038 loss in 2Q 2021) Second quarter 2022 results: CA$0.016 loss per share (up from CA$0.038 loss in 2Q 2021). Revenue: CA$1.28m (up 19% from 2Q 2021). Net loss: CA$1.75m (loss narrowed 43% from 2Q 2021). Reported Earnings • Aug 01
First quarter 2022 earnings released: CA$0.011 loss per share (vs CA$0.023 loss in 1Q 2021) First quarter 2022 results: CA$0.011 loss per share (up from CA$0.023 loss in 1Q 2021). Revenue: CA$2.28m (up CA$1.93m from 1Q 2021). Net loss: CA$1.11m (loss narrowed 23% from 1Q 2021). Board Change • Apr 27
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 2 experienced directors. No highly experienced directors. CFO, Corporate Secretary & Director Shaun Power is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Dec 02
Third quarter 2020 earnings: Revenues and EPS in line with analyst expectations Third quarter 2020 results: CA$0.23 loss per share (down from CA$0.032 loss in 3Q 2019). Revenue: CA$182.5k (down 45% from 3Q 2019). Net loss: CA$4.62m (loss widened CA$3.97m from 3Q 2019). Revenue was in line with analyst estimates. Board Change • Sep 15
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (4 non-independent directors). CFO, Corporate Secretary & Director Shaun Power is the most experienced director on the board, commencing their role in 2020. Independent Director Lino Fera was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Board Change • Sep 10
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (4 non-independent directors). CFO, Corporate Secretary & Director Shaun Power is the most experienced director on the board, commencing their role in 2020. Independent Director Lino Fera was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Board Change • Sep 07
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (4 non-independent directors). CFO, Corporate Secretary & Director Shaun Power is the most experienced director on the board, commencing their role in 2020. Independent Director Lino Fera was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Board Change • Sep 01
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (4 non-independent directors). CFO, Corporate Secretary & Director Shaun Power is the most experienced director on the board, commencing their role in 2020. Independent Director Lino Fera was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. 
